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Edited by Vladimir SkulachevAbstract Histamine and thrombin cause phosphorylation and
activation of endothelial NO-synthase (eNOS) on Ser1177. We
tested the role of various protein kinases in mediating this eﬀect
in human umbilical vein endothelial cells. Inhibition of the Ca2þ/
calmodulin-dependent protein kinase II or phosphoinositide 3-
kinase (PI3K) had no eﬀect. H89, an inhibitor of both protein
kinase A (PKA) and 50-AMP-activated protein kinase (AMPK),
strongly inhibited phosphorylation and activity of eNOS. Con-
versely, the PKA inhibitor Rp-adenosine 3050-cyclic monophos-
phate (cAMPS) had no eﬀect and eNOS was not phosphorylated
by treatments that aﬀect cAMP levels. Thrombin and histamine
caused phosphorylation of AMPK on Thr172 as well as on its
downstream target acetyl-CoA carboxylase. Activation of
AMPK using AICAR or CCCP also resulted in eNOS
phosphorylation. We conclude that histamine and thrombin
cause eNOS phosphorylation in an AMPK mediated manner,
independent of P13K-Akt.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Given the central position of the vascular endothelium in
early atherogenesis and the vast number of blood borne
chemical, cellular and rheological stimuli that continuously
aﬀect endothelial cells, the signal transduction mechanisms
involved in linking exposure to endothelial response have in
recent years attracted considerable attention. Among the nu-
merous biologically important molecules produced by the* Corresponding author. Fax: +354 5255140.
E-mail address: brynhit@hi.is (B. Thors).
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monophosphate; AMPK, 50-AMP-activated protein kinase; ATP,
adenosine 50-triphosphate; CaMKII, Ca2þ/calmodulin-dependent pro-
tein kinase II; cAMP, adenosine 3050-cyclic monophosphate; EGF,
epidermal growth factor; eNOS, endothelial NO-synthase; HUVEC,
human umbilical vein endothelial cells; NO, nitric oxide; PI3K,
phosphoinositide 3-kinase; PKA, protein kinase A; PKC, protein
kinase C; PLC, phospholipase C; ROCK, Rho-dependent protein
kinase
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doi:10.1016/j.febslet.2004.07.078vascular endothelium, nitric oxide (NO) seems to play a par-
ticularly important role in regulating cardiovascular homeo-
stasis. It aﬀects blood vessel dilation and hence vascular
resistance and blood pressure, angiogenesis, apoptosis, adhe-
sion of platelets and monocytes to the endothelium, endothe-
lin-1 generation and vascular smooth muscle cell proliferation
[1].
The major source of NO is endothelial NO-synthase (eNOS)
which is regulated by a complex battery of regulatory mech-
anisms, including subcellular localization in caveoli where in-
teraction of eNOS with caveolin and heat shock protein 90
exempliﬁes a regulatory protein-protein interaction [2]. Regu-
lation with phosphorylation has also been reported and re-
cently speciﬁc sites for phosphorylation of eNOS and speciﬁc
protein kinases mediating the phosphorylation have been
identiﬁed. These include protein kinase B (PKB)/Akt [3],
protein kinase A (PKA) [4], protein kinase C (PKC) [5], 50-
AMP-activated protein kinase (AMPK) [6,7] and Ca2þ/cal-
modulin-dependent protein kinase II (CaMKII) [8], Michell
and coworkers have published data suggesting that regulation
of eNOS activity involves coordinated phosphorylation and
dephosphorylation of Ser1179 and Thr497 residues on bovine
eNOS by multiple protein kinases and phosphatases with
stimulation, involving phosphorylation at Ser1179 and de-
phosphorylation at Thr497 [5]. Bradykinin has been shown to
activate eNOS phosphorylation at Ser1179 either in an Akt [9]
or CaMKII [8] dependent manner while stimulating dephos-
phorylation of Thr497 through a calcineurin mediated, Akt
independent mechanism [9]. Adiponectin was also recently
shown to cause eNOS phosphorylation at Ser1179. This
phosphorylation was inhibited by wortmannin but was still
Akt independent and mediated partially by AMPK [7]. Others
have implicated Akt in eNOS phosphorylation caused by
adiponectin, demonstrating a cross-talk between AMPK and
Akt in endothelial cells [10].
AMPK is the central component of a protein kinase cascade
that plays an important role in the regulation of energy me-
tabolism, often referred to as the cell’s metabolic master switch
[11]. In response to a decrease in the energy state of a cell,
AMPK is phosphorylated and activated by a still not fully
characterized upstream pathway. Once activated, AMPK
phosphorylates multiple targets, all aimed at restoring
adenosine 50-triphosphate (ATP) levels. These include ace-
tyl CoA carboxylase (ACC), hydroxymethylglutaryl-CoAation of European Biochemical Societies.
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phosphorylation of eNOS at Ser1177 by AMPK is Ca2þ/CaM
dependent [6].
We have previously shown in primary cultures of human
umbilical vein endothelial cells (HUVEC) that thrombin and
histamine, although inhibiting Akt phosphorylation when
applied in cotreatment with epidermal growth factor, stimulate
eNOS phosphorylation at Ser1177 [12].
In this paper, we explore the role of various protein kinases
in mediating the stimulatory eﬀects of the G-protein activators
thrombin and histamine on eNOS Ser1177 phosphorylation.
Our results demonstrate that AMPK mediates the stimulatory
eﬀects of both agonists through a phosphoinositide 3-kinase
(PI3K)-Akt independent pathway.Fig. 1. The eﬀect of EGF, histamine or thrombin on eNOS phos-
phorylation (Ser1177). Cells were treated with wortmannin (100 nM)
for 10 min before treatment with EGF (10 ng/mL, 5 min), histamine
(10 lM, 10 min) or thrombin (1 U, 5 min). The eﬀect of Y 27632 (10
lM, 20 min) on histamine or thrombin mediated eNOS phosphory-
lation. Conﬂuent endothelial cells were stimulated as indicated, lysates
were electrophorized and blotted as described in methods and detected
using antibody against eNOS and the Serl177 phosphorylated eNOS.
Each Western blot is representative of three independent experiments.2. Materials and methods
2.1. Materials
Morgan’s medium 199, fetal bovine serum and Penicillin–Strep-
tomycin were purchased from Gibco-BRL, Life Technologies. Tissue
culture plates (35 mm) were from Nunc, Cryotin X (collagenase)
from cod was provided by The Science Institute of Iceland. Epi-
dermal growth factor (EGF), 12-O-tetradecanoylphorbol-13-acetate
(TPA), histamine, thrombin, carbonyl cyanide m-chlorophenylhyd-
razone (CCCP), 1-isobutyl-3-methyl xanthine (IBMX), 8-bromo-
adenosine 3050-cyclic monophosphate (cAMP), Rp-cAMPS, A23187,
U73122, forskolin and wortmannin were purchased from Sigma.
H89 was from Biomol. 5-aminoimidazole-4-carbozamide-l-b-4 ribo-
furanoside (AICAR), BAPTA/AM, KN-93 and Y 27632 were from
Calbiochem. Myo[3H]inositol, Hybond ECL Nitrocellulose mem-
brane (68 cm), ECL + PLUS Western blotting detection system,
Hyperﬁlm ECL High performance chemiluminescence ﬁlm and L-
(3H) arginine (61.0 Ci/mmol) were from Amersham Pharmacia
Bioteck. Antibodies against phospho-eNOS (Ser1177), AMPK,
phospho-AMPK (Thrl72) and Anti-Rabbit IgG/HRP-linked came
from Cell Signaling Technology. eNOS antibody came from Trans-
duction Laboratories and pACC (Ser79) and ACC antibodies from
Upstate, Poly-prep preﬁlled chromatography columns were from
BioRad.
2.2. Endothelial cell culture
Endothelial cells were cultured from human umbilical veins by a
modiﬁcation of the method of Jaﬀe et al. as previously reported [13].
The cells were harvested by Cryotin X collagenase digestion and see-
ded on 35 mm culture dishes in medium 199 containing 20% fetal
bovine serum and antibiotics (penicillin, 100 units/mL and strepto-
mycin, 100 lg/mL). The culture dishes were incubated at 37 C in
humidiﬁed air with 5% CO2. The medium was changed 24 h after
seeding the cells and every 2–3 days thereafter until the cell culture
reached conﬂuence (after 7 days).
When conﬂuent, the cells were washed with Morgan’s medium 199
and then placed in 1.0 mL Morgan’s medium 199 with or without
inhibitors at the indicated concentrations. 10–20 min later, agonist was
added in a concentration calculated to reach the intended concentra-
tion for each experiment and left on for additional 2–20 min. The
agonists were then removed along with the medium and cellular
reactions terminated by adding 250 lL SDS sample buﬀer. The sam-
ples were boiled for 5 min and centrifuged for 10 min at 3000 rpm.
After that, the samples were ready to be used or could be stored at
)20 C.
2.3. Electrophoresis and immunoblotting
Samples (8 lL) were resolved by SDS–PAGE (10%). The gels were
blotted and the proteins thereby transferred to nitrocellulose. The
membranes were hybridized with the indicated antibodies and later
with a secondary antibody (Anti-Rabbit IgG/HRP-linked). The im-
muno-complexes were detected with ECL+PLUS Western blotting
detection system and developed onto a ﬁlm. Equal loading was as-
certained by hybridizing membranes with antibodies against unphos-
phorylated protein.2.4. Determination of eNOS activity
eNOS activity in intact cells was determined by monitoring the
conversion of incorporated L-(3H) arginine into L-(3H) citrulline as
described by Schmidt and Mayer [14]. Brieﬂy, the cells were washed
and equilibrated for 20 min in incubation buﬀer (50 mM Tris buﬀer,
pH 7.4, containing 100 mM NaCl, 5 mM KC1, 1 mM MgCl2, and 2
mM CaCl2) with or without BAPTA or H89. Reactions were started
by the addition of L-(3H) arginine (61.0 Ci/mmol, l lCi, ﬁnal con-
centration 16 nM) and the agonist. After 3 min the cells were washed
with chilled incubation buﬀer containing 0.1 mM EGTA instead of
CaCl2, followed by the addition of 1 mL of 10 mMHCl. An hour later,
an aliquot was removed for determining the incorporated radioactiv-
ity. To the remaining sample a solution of 200 mM sodium acetate, 20
mM NaOH containing 10 mM citrulline was added (ﬁnal pH approx.
5.0) and L-(3H) citrulline was separated from L-(3H) arginine by cation
exchange chromatography [14].3. Results
3.1. Eﬀects of EGF, histamine and thrombin on eNOS
phosphorylation
Fig. 1 demonstrates the eﬀects of EGF, histamine and
thrombin on Serl177 phosphorylation of eNOS. As seen, the
PI3K inhibitor wortmannin totally blocked the eﬀect of EGF
whereas phosphorylation by histamine and thrombin was un-
aﬀected, demonstrating diﬀerent pathways mediating phos-
phorylation by these agonists.
3.2. Histamine and thrombin mediated eNOS phosphorylation is
dependent on Ca2þ but independent of CaMKII
As shown in Fig. 2A, U73122, an inhibitor of phospholipase
Cb (PLCb), inhibited the histamine mediated phosphorylation
of eNOS. Conversely, the eﬀects of the Caþ2 ionophore
A23187 were not aﬀected. The calcium chelator BAPTA
blocked the phosphorylation by thrombin and histamine as
well as that caused by A23187 (Fig. 2A).
One of the downstream eﬀectors of Ca2þ/CaM is CaMKII,
which has been implicated in eNOS phosphorylation after
bradykinin treatment [8]. As seen in Fig. 2A, the CaMKII
inhibitor KN-93 had no eﬀect on eNOS phosphorylation
caused by histamine or thrombin. The results suggest that
Fig. 2. The role of various protein kinases in eNOS phosphorylation
(Serl177). (A) The cells were treated with U73122 (10 lM) for 20 min
before treatment with histamine (10 lM, 3 min) or A23187 (200 nM, 3
min). The eﬀect of a 20 min pre-treatment with BAPTA (30 lM) or
KN-93 (30 lM) on histamine (10 lM, 5 min), thrombin (1 U, 5 min) or
A23198 (200 nM, 3 min) mediated eNOS phosphorylation. The eﬀect
of TPA (100 ng/mL, 7 min) on eNOS phosphorylation. (B) The eﬀect
of Rp-cAMPS (10 lM, 20 min) on eNOS phosphorylation after
thrombin (1 U, 2 min). The eﬀect of BMX + forskolin (100 lM/10 lM,
20 min), thrombin (1 U, 10 min) and 8-bromo-cAMP (100 lM, 10 min)
on eNOS phosphorylation. (C) Cells were treated with H89 (20 lM)
for 10 min before treatment with histamine (10 lM, 3 min) or
thrombin (1 U, 10 min). Samples were separated by SDS–PAGE and
analyzed by Western blotting. Each Western blot is representative of
three independent experiments.
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dependent on a Ca2þ signal without involving CaMKII.
3.3. PKC and PKA are not involved in histamine or
thrombin-induced eNOS phosphorylation at Ser 1177
In addition to Ca2þ elevation, activation of PI speciﬁc PLC
in HUVEC leads to activation of PKC. Therefore, we testedthe eﬀect of the PKC activator TPA on eNOS phosphoryla-
tion. As seen in Fig. 2A, TPA had no eﬀect.
To test the possible eﬀect of PKA on eNOS phosphoryla-
tion, the cells were treated either with substances increasing
intracellular cAMP (IBMX and forskolin or 8-bromo-cAMP)
or with the PKA inhibitors Rp-cAMPS or H89. None of the
substances increasing cAMP levels had any eﬀect on eNOS
phosphorylation nor did Rp-cAMPS prevent the phosphory-
lation of eNOS after thrombin treatment (Fig. 2B). Con-
versely, H89 totally inhibited both histamine and thrombin
stimulated eNOS phosphorylation (Fig. 2C). The inhibition
was 964% based on scanning three independent gels.3.4. The role of AMPK in eNOS phosphorylation caused by
histamine or thrombin
Although marketed as ‘‘a selective and potent inhibitor of
PKA’’, Cohen and coworkers [15] have shown that H89 in-
hibits several protein kinases to a similar degree, including
AMPK. As AMPK has been shown to phosphorylate eNOS
[6,7], we tested the eﬀects of histamine and thrombin on
AMPK activity.
Both histamine and thrombin caused phosphorylation of
AMPK (Thrl72) and the AMPK substrate ACC (Ser79)
(Fig. 3A). The phosphorylation of AMPK and ACC was un-
aﬀected by wortmannin, but inhibited by the Ca2þ chelator
BAPTA (Fig. 3A). Furthermore, H89 inhibited ACC phos-
phorylation caused by histamine or thrombin (97  3% inhi-
bition, quantiﬁed by scanning three independent gels), whereas
AMPK phosphorylation was not aﬀected (Fig. 3A). AMPK,
eNOS and ACC phosphorylation was also caused by CCCP,
which activates AMPK by lowering the ATP/AMP ratio [16]
(Fig. 3B). AICAR, which mimicks the activating eﬀect of AMP
on AMPK without aﬀecting the AMP/ATP ratio [17] also
caused phosphorylation of AMPK, eNOS and ACC (Fig. 3C).
All the eﬀects of thrombin, histamine and CCCP on eNOS
phosphorylation were independent of PI3K (Figs. 1 and 3B),
whereas H89 inhibited phosphorylation of eNOS after all these
treatments (Figs. 2C and 3B). Finally, the Ca2þ ionophore
A23187 mimicked the eﬀects of thrombin and histamine on the
phosphorylation of AMPK, eNOS and ACC (Fig. 4). These
eﬀects of A23187 on eNOS phosphorylation were inhibited by
H89 and BAPTA but unaﬀected by wortmannin (Figs. 2A and
4A). BAPTA also prevented the phosphorylation of AMPK by
A23187 (Fig. 4B). As with eNOS, the PLC inhibitor U73122
prevented the histamine mediated AMPK phosphorylation but
had no eﬀect on the phosphorylation mediated by A23187
(Fig. 4B).
As H89 has been shown to inhibit Rho-dependent protein
kinase II (ROCK-II) [15] as well as AMPK, and ROCK-II can
regulate eNOS expression and phosphorylation [18], we tested
the eﬀects of the ROCK-II inhibitor Y 27632. As seen in Fig. 1,
inhibiting ROCK-II had no eﬀect on eNOS phosphorylation.3.5. eNOS activation in response to histamine or thrombin
In order to determine whether histamine or thrombin
treatment led to the activation of eNOS, we studied their eﬀect
on the conversion of L-(3H) arginine to L-(3H) citrulline. Both
agonists caused threefold increase in citrulline formation
(Fig. 5) and this activation was largely prevented by pre-
treatment with H89 or BAPTA. BAPTA also caused a de-
crease in the basal rate of conversion to L-(3H) citrulline. As
Fig. 3. The role of AMPK in eNOS phosphorylation (Ser1177). (A) The eﬀect of wortmannin (100 nM, 10 min), BAPTA (30 lM, 10 min) or H89 (20
lM, 20 min) on histamine (10 lM, 5 min) or thrombin (1 U, 5 min) mediated phosphorylation ofAMPK (Thrl72) or ACC (Ser79). (B) The eﬀect of a
20 min pre-treatment with wortmannin (100 nM) or H89 (20 lM) on eNOS or AMPK phosphorylation caused by CCCP (10 lM, 3 min). The eﬀect
of CCCP (10 lM, 10 min) on ACC phosphorylation. (C) Cells were treated with AICAR (2 mM) for 4 h (eNOS, ACC) or 6 h (AMPK). The AICAR
treatments were performed in medium containing 20% serum. Samples were separated by SDS–PAGE and analyzed by Western blotting. Each
Western blot is representative of three independent experiments.
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agonists, the activation was shortlived, being almost over in 3
min (not shown).4. Discussion
In this paper, we show that both histamine and thrombin
cause eNOS phosphorylation at Ser1177 in HUVEC in an
AMPK mediated manner, independent of PI3K-Akt. Several
protein kinases have been implicated in eNOS phosphoryla-
tion at Ser1177. We demonstrate that the phosphorylation
caused by histamine and thrombin is Ca2þ dependent, without
the involvement of PKC or CaMKII. Also, results from var-
ious manipulations aﬀecting cAMP levels weighed against the
possibility that PKA mediated the eNOS phosphorylation
caused by these G-protein agonists. It has been shown that
AMPK can phosphorylate eNOS on Ser1177 [6,20] and eNOS
has been reported to be in a complex with AMPK [6,21]. We
show that histamine and thrombin cause phosphorylation of
AMPK on Thrl72 and that wortmannin had no eﬀect on his-
tamine or thrombin-mediated phosphorylation of either eNOS
or AMPK. Other substances, such as the mitochondrial un-
coupler CCCP and AICAR, which cause AMPK phosphory-
lation [16,17], also caused eNOS phosphorylation in our cells
further supporting our conclusion that histamine and throm-
bin stimulate phosphorylation of eNOS in an AMPK-depen-dent manner. Using an L-(3H) citrulline conversion assay, we
demonstrate that treatment with histamine or thrombin actu-
ally leads to eNOS activation. The inhibition of AMPK
phosphorylation as well as eNOS phosphorylation by U73122
suggests that histamine and thrombin mediate their activation
by Gq. Histamine and thrombin are known to activate PLC in
HUVEC [22] and Gq coupled receptors cause activation of
AMPK [23].
Previously, it has been reported that the G-protein activator
bradykinin stimulates phosphorylation of eNOS on Ser1177
via CaMKII [8]. However, while we found that histamine and
thrombin mediated phosphorylation of eNOS was Ca2þ de-
pendent, inhibited by the Ca2þ chelator BAPTA and mimicked
by the Ca2þ ionophore A23187, it was unaﬀected by the
CaMKII inhibitor KN-93. Treatment with TPA had no eﬀects
on eNOS Ser1177 phosphorylation, thereby ruling out PKC
mediated eﬀects of histamine or thrombin. The inhibition by
H89, however, suggested a possible involvement of PKA as
had been demonstrated for eNOS phosphorylation caused by
shear stress and bradykinin [4,24]. However, H89 is not a
speciﬁc PKA inhibitor and has been reported to inhibit several
other protein kinases including AMPK and ROCK-II [15].
Also, Rp-cAMPS, a structurally unrelated PKA inhibitor, was
without eﬀect on eNOS phosphorylation. Finally, manipula-
tion of cAMP levels had no eﬀect on eNOS phosphorylation in
our cells, indicating that the involvement of PKA in this
pathway is unlikely. Therefore, we conclude that the H89 in-
Fig. 4. The involvement of Ca2þ in eNOS (Ser1177) or AMPK
(Thrl72) phosphorylation. (A) The eﬀect of A23187 (200 nM, 3 min).
The cells were treated with wortmannin (100 nM) or H89 (20 lM) for
20 min before treatment with A23187. (B) The cells were treated with
BAPTA (30 lM) for 20 min before treatment with A23187 (200 nM, 3
min). The eﬀect of U73122 (10 lM, 20 min) on histamine (10 lM, 3
min) or A23187 (200 nM, 3 min) mediated AMPK phosphorylation.
Samples were separated by SDS–PAGE and analyzed by Western
blotting. Each Western blot is representative of three independent
experiments.
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Fig. 5. eNOS activation in response to histamine or thrombin. Eﬀect of
histamine (10 lM, 3 min) or thrombin (1 U, 3 min) on eNOS activa-
tion and the eﬀect of 20 min pre-treatment with H89 (20 lM) or
BAPTA (30 lM) on eNOS activation caused by histamine. The results
show the average  S.D. of three experiments each done in duplicate.
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This is further supported by our ﬁnding that H89 inhibits the
phosphorylation of the AMPK substrate ACC but not the
phosphorylation of AMPK itself.
It has repeatedly been shown that regulation of eNOS is a
complex, multifactorial process [2]. Harris et al. [9] concluded
that bradykinin stimulates eNOS phosphorylation via PI3K/
Akt. After bradykinin treatment they demonstrated Akt
phosphorylation and eNOS phosphorylation which were in-
hibited by wortmannin [9]. However, others have demon-
strated wortmannin sensitive phosphorylation of eNOS which
is Akt independent. Thus, shear stress mediated eNOS phos-Histamine
Thrombin
PLC
IP3
Ca+2
CaM
AMP / A
BAPTA
DAG
U73122
↑ ↓
Fig. 6. A proposed pathway for thrombin and histamine-mediated eNOS activ
and release of Ca2þ initiating energy requiring processes and activation of A
Ca2þ levels activates eNOS to produce NO.phorylation is mediated by PKA [4] and adiponectin mediated
eNOS phosphorylation is mediated by AMPK [7]. Further
complications were recently reported by Ouchi et al. [10] who
demonstrated that Akt functions downstream of AMPK
in adiponectin stimulated endothelial cells, suggesting the
following signaling pathway: adiponectin-AMPK-PI3K-
Akt-eNOS. However, in all those cases, eNOS phosphoryla-
tion mediated by AMPK was P13K dependent. In contrast, in
the experiments reported in this paper, wortmannin did not
inhibit eNOS phosphorylation caused by histamine or
thrombin, clearly demonstrating a P13K-independent pathway
distinct from those activated by the other G-protein agonists,
adiponectin and bradykinin. Our ﬁnding that BAPTA inhibits
the phosphorylation of AMPK, eNOS and ACC together with
the observation that all these phosphorylations are mimicked
by treatment with the Ca2þ ionophore A23187, suggests that a
Ca2þ signal is upstream of AMPK phosphorylation in
thrombin or histamine stimulated endothelial cells.eNOS
TP
AMPK
H89
NO
ation. Thrombin and histamine activate PLC, causing formation of IPs
MPK. AMPK phosphorylates eNOS and this together with increased
180 B. Thors et al. / FEBS Letters 573 (2004) 175–180Finally, the inhibition by H89 and BAPTA in the citrulline
assay suggests the importance of Ser1177 phosphorylation in
the activation of eNOS following histamine treatment.
Thrombin, histamine and A23187 have previously been
shown to cause a transient phosphorylation of elongation
factor 2 (eEF2) [25] which is downstream of AMPK [26], and
thus to temporarily inhibit protein synthesis. This eﬀect is
mimicked by treatments that lower ATP levels (oligomycin
and CCCP) [16]. We speculate (Fig. 6) that the activation of
AMPK that we describe in HUVEC is mediated by lowered
ATP levels. Both thrombin and histamine cause activation of
phospholipase C leading to a Ca2þ signal resulting in synthesis
of prostacyclin and platelet activating factor, release of von
Willenbrands factor and induction of shape change, all pro-
cesses which require ATP. Inhibition of PLC by U73122 pre-
vented the phosphorylation of both AMPK and eNOS after
histamine stimulation but not after treatment with the Ca2þ
ionophore A23187 (PLC independent).
In conclusion, in HUVEC we have demonstrated a role for
AMPK in a pathway mediating stimulatory signals from G-
protein coupled receptors causing eNOS phosphorylation in a
PI3K-Akt independent manner.
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